Provided herein are compounds of the Formula I: ##STR00001##
and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Provided herein are compounds of the Formula I: ##STR00001##
and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Provided herein is a compound of the Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

Provided herein is a compound of the Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.

This invention is related to 3-(2-(4-(2-methoxyphenyl)piperazine-1-yl) ethyl) quinazoline-4(3H)-one, pharmaceutically acceptable salts, enantiomers, diasteroisomers, stereoisomers, crystals, hydrates, solvates, prodrugs, and metabolites thereof for the treatment of Post-Traumatic Syndrome Disorder (PTSD), and pharmaceutical compositions containing the compounds for the treatment of Post-Traumatic Syndrome Disorder (PTSD).

This invention is related to 3-(2-(4-(2-methoxyphenyl)piperazine-1-yl) ethyl) quinazoline-4(3H)-one, pharmaceutically acceptable salts, enantiomers, diasteroisomers, stereoisomers, crystals, hydrates, solvates, prodrugs, and metabolites thereof for the treatment of Post-Traumatic Syndrome Disorder (PTSD), and pharmaceutical compositions containing the compounds for the treatment of Post-Traumatic Syndrome Disorder (PTSD).

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.